Forxiga CKD Japan Post-Marketing Surveillance (PMS)

AstraZeneca

Status: Completed

Conditions: Chronic Kidney Disease

Study type: Observational

Funder types: Industry

Identifiers

NCT05306210

D169AC00007

Details and patient eligibility

About

To capture safety when Forxige is administrated to CKD patients in the real world setting

Full description

The purpose of the study is to review the following points during use of Forxiga Tablets (hereinafter referred to as Forxiga) in the real world setting after launch for treatment of CKD.

1. ADRs which are unexpected from the precautions for use in our JPI
2. Understanding of incidence of ADRs during use of Forxiga in the real world setting
3. Factors (ie demography, treatment) possibly having an impact on the safety.

Enrollment: 1,029 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with CKD except for dialysis and/or renal failure chronic

Exclusion criteria

• None